Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT06446726
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Zachary Zumsteg
- Target Recruit Count
- 50
- Registration Number
- NCT06445114
- Locations
- 🇺🇸
Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸CS Cancer at Valley Oncology Medical Group, Tarzana, California, United States
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
- Conditions
- Unresectable Perihilar or Ductal CCAExtrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 42
- Registration Number
- NCT06440993
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Universitätsklinikum Düsseldorf, Düsseldorf, Germany
🇩🇪Universitätsklinikum Köln, Köln, Germany
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- Radiation: Proton Beam TherapyDrug: Concurrent oral capecitabine chemotherapyProcedure: Orthotropic Liver Transplant
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 30
- Registration Number
- NCT06434493
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Conditions
- Lung DiseasesCarcinoma, Non-Small-Cell LungResectable Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 129
- Registration Number
- NCT06431633
- Locations
- 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06426056
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
- Conditions
- Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic AdenocarcinomaStage I Pancreatic Cancer AJCC V8Stage II Pancreatic Cancer AJCC V8Stage III Pancreatic Cancer AJCC V8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Pancreatic Surgical Procedure
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT06423326
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- Conditions
- Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06422858
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Radiation: Brachytherapy and External Beam Radiotherapy
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Target Recruit Count
- 240
- Registration Number
- NCT06419673
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.